Autoimmune Diseases  >>  Actemra SC (tocilizumab SC)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Actemra SC (tocilizumab SC) / Roche, Halozyme
NCT00965653: A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis

Completed
1
29
Canada, Europe, RoW
folic acid, methotrexate, tocilizumab [RoActemra/Actemra]
Hoffmann-La Roche
Rheumatoid Arthritis
 
07/11
NCT02404558: Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis

Completed
1
30
Japan
sarilumab SAR153191 (REGN88), tocilizumab
Sanofi, Regeneron Pharmaceuticals
Rheumatoid Arthritis
03/16
03/16
JIGSAW 117, NCT01904279 / 2012-003486-18: A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)

Completed
1
52
US, Canada, Europe, RoW
Tocilizumab, RoActemra/Actemra
Hoffmann-La Roche
Juvenile Idiopathic Arthritis
05/16
05/16
NCT01904292 / 2012-003490-26: A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis

Completed
1
52
US, Canada, Europe, RoW
Tocilizumab, RoActemra/Actemra
Hoffmann-La Roche
Juvenile Idiopathic Arthritis
06/17
06/17

Download Options